Background: ABL1 tyrosine kinase inhibitor discontinuation securely became among the
therapeutic goal for chronic myeloid leukemia chronic phase patients (CML-CP). To …

Objective Treatment-free remission (TFR) after tyrosine kinase inhibitor (TKI) discontinuation
at the first attempt is a therapeutic goal for patients with chronic phase chronic myeloid …

Simple Summary Tyrosine kinase inhibitors (TKIs) have dramatically improved the treatment
of chronic myeloid leukemia (CML). Recently, TKIs were discontinued in patients with CML …

Introduction: Treatment-free remission (TFR) as one of the goals of treatment of BCR:: ABL-
positive chronic phase chronic myeloid leukemia (CML) has been proposed. Actually …

Background Long‐term treatment‐free remission (TFR) represents a new goal for chronic
myeloid leukemia (CML). In clinical practice, tyrosine kinase inhibitor (TKI) dose reductions …

Background: Long‐term treatment‐free remission (TFR) represents a new goal for chronic
myeloid leukemia (CML). Optimizing dose of tyrosine kinase inhibitors (TKIs) in the CML …

Background: After long-term treatment with tyrosine kinase inhibitors (TKIs), an important
proportion of patients with chronic myeloid leukemia (CML) achieve and maintain a deep …

Introduction: Achieving a major molecular response (MMR) defined as BCR:: ABL1≤ 0.1%
IS, is an important milestone for optimal response in patients with chronic myeloid leukemia …

Background: The development of tyrosine kinase inhibitor (TKI) therapy has positively
impacted the survival rates of patients with chronic myeloid leukemia (CML). It is common in …

Introduction: An attempt at tyrosine kinase inhibitor (TKI) withdrawal in deep molecular
remission leads either to treatment free remission (TFR) or early molecular relapse (MolR) in …